Synthesis, Molecular Docking, and Biological Evaluation of Pyridin-3-yl-Pyrimidin-2-yl-Triazole Derivatives as Anti-cancer Agents

Abstract

In this work, novel imatinib-based compounds were synthesized, characterized, and evaluated against, PC3, Panc1, MDA-MB-231, and K562. The synthetic procedure was started from methyl-4-hydroxy benzoate and afforded the desired compounds through six steps. Among synthesized compounds, N-(4-Methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((1-(2-((4-methyl-3-nitrophenyl)amino)-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methoxy)benzamide, 11q was found effective against cancer cell lines. Interestingly, the activity of compound 11q was higher than Imatinib (as the standard control). Besides, three-dimensional cell culture along with DAPI-staining assay was performed to get insight about the mechanism of activity. Molecular docking pointed out that triazole moiety formed hydrogen bond and has an important effect on observed activity.

Keywords:

• Triazole
• click chemistry
• cancer
• apoptosis
• imatinib

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This work was supported and funded by Tehran University of Medical Sciences, Grant no. 99-1-104-46996.